公开(公告)号：CA2781433C

公开(公告)日：2019-04-09

申请号：CA2781433

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K38/38 ,  A61K38/16 ,  A61P35/04 ,  C07K14/09 ,  C07K14/76

Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.

公开(公告)号：GB2464028B

公开(公告)日：2011-06-01

申请号：GB201000660

申请日：2008-05-30

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  HUANG CHUN-YUNG ,  LIANG CHI-MING

IPC: C07K14/09 ,  A61K38/16 ,  A61K38/38 ,  A61K38/39 ,  A61P35/00 ,  C07K1/18 ,  C07K14/76 ,  C07K14/78

公开(公告)号：GB2460966A

公开(公告)日：2009-12-23

申请号：GB0913559

申请日：2008-05-30

Applicant: ACADEMIA SINICA

Inventor： HUANG CHUN-YUNG ,  LIANG SHU-MEI

IPC: C07K14/78 ,  A61K38/39 ,  A61P35/00 ,  A61P37/04

Abstract: An isolated protein comprising an RGD motif and having a fibrillar structure, for use in medicine, is disclosed. The RGD-containing protein is preferably fibronectin, and may be used in the treatment of cancer, particularly kidney, breast, lung or ovarian cancer. The protein may induce cell death by modulating an Akt signaling pathway. The protein may also be used as an adjuvant.

公开(公告)号：AU2010321830B2

公开(公告)日：2015-06-11

申请号：AU2010321830

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K38/38 ,  A61K38/16 ,  A61K47/48 ,  C07K14/76

Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment

公开(公告)号：DE602007003944D1

公开(公告)日：2010-02-04

申请号：DE602007003944

申请日：2007-01-03

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  LIN NA-SHENG ,  HSU YAU-HEIU ,  LIAO JIA-THE

IPC: C12N15/40 ,  A61K38/16 ,  C07K14/08 ,  C07K14/09 ,  C12N5/14 ,  C12N15/42 ,  C12N15/62 ,  C12N15/79 ,  C12N15/82 ,  C12N15/83

Abstract: Disclosed are nucleic acids encoding fusion polypeptides containing the sequence of a Bamboo mosaic virus coat protein or a segment thereof; and an immunogenic heterologous fragment that is fused to the carrier fragment. Also disclosed are related chimeric bamboo mosaic virus particle, related expression vectors, related host cells, and related compositions. Methods of producing and using the fusion polypeptide or chimeric Bamboo mosaic virus particle are also disclosed.

公开(公告)号：AT452978T

公开(公告)日：2010-01-15

申请号：AT07100073

申请日：2007-01-03

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  LIN NA-SHENG ,  HSU YAU-HEIU ,  LIAO JIA-THE

IPC: C12N15/40 ,  C07K14/08 ,  C07K14/09 ,  C12N15/42 ,  C12N15/62 ,  C12N15/79 ,  C12N15/82 ,  C12N15/83

Abstract: Disclosed are nucleic acids encoding fusion polypeptides containing the sequence of a Bamboo mosaic virus coat protein or a segment thereof; and an immunogenic heterologous fragment that is fused to the carrier fragment. Also disclosed are related chimeric bamboo mosaic virus particle, related expression vectors, related host cells, and related compositions. Methods of producing and using the fusion polypeptide or chimeric Bamboo mosaic virus particle are also disclosed.

公开(公告)号：EP1765392A4

公开(公告)日：2007-10-17

申请号：EP05757499

申请日：2005-06-08

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K39/12 ,  A61K38/00 ,  A61K38/06 ,  A61K38/16 ,  A61K39/00 ,  A61K39/125 ,  A61K39/135 ,  C07K1/113 ,  C07K14/005 ,  C07K14/09 ,  C12N7/00 ,  C12N7/01

CPC classification number: C07K14/005 ,  A61K31/7088 ,  A61K38/162 ,  A61K39/00 ,  A61K39/12 ,  A61K39/135 ,  A61K2039/523 ,  C07K1/1136 ,  C12N2770/32122 ,  C12N2770/32133

公开(公告)号：EP2501402A4

公开(公告)日：2013-05-01

申请号：EP10832290

申请日：2010-11-19

Applicant: ACADEMIA SINICA

Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

IPC: A61K38/38 ,  A61K47/48 ,  C07K14/76

CPC classification number: A61K38/385 ,  A61K38/162 ,  A61K38/38 ,  A61K45/06 ,  A61K47/643 ,  A61N5/10 ,  C07K14/765 ,  C12N7/00 ,  C12N2770/32133

Abstract: Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer.